论文部分内容阅读
目的探讨孟鲁司特钠联合氨溴特罗治疗婴幼儿喘息性支气管炎的临床疗效。方法将160例喘息性支气管炎患儿分为治疗组和对照组各80例,两组均给抗病毒(合并细菌感染者给予抗生素疗)、口服氨溴特罗口服液氧驱雾化吸入布地奈德、吸氧、吸痰及支持治疗。治疗组在对照组基础上加用口服孟鲁司特钠。统计分析两组的治疗效果,并对结果进行分析。结果治疗组总有效率为98.7%,高于对照组的77.5%,两组比较差异有统计学意义(P<0.05)。结论孟鲁司特钠能有效的降低喘息性支气管炎患儿黏膜分泌、减少气道水肿、减轻支气管痉挛、缓解哮喘症状;氨溴特罗使痰容易咳出,且减轻咳嗽,能有效解除支气管痉挛,两者联用有效改善患儿的肺功能,值得临床推广应用。
Objective To investigate the clinical efficacy of montelukate combined with ambroxol on infantile asthmatic bronchitis. Methods 160 cases of asthmatic bronchitis were divided into treatment group and control group 80 cases, both groups were given antivirus (antibiotics combined with bacterial infection), oral administration of ambroxol oral oxygen inhalation cloth Ned, oxygen, suction and supportive treatment. Treatment group in the control group plus oral montelukast sodium. Statistical analysis of the two groups of treatment, and the results were analyzed. Results The total effective rate in the treatment group was 98.7%, which was higher than that in the control group (77.5%). There was significant difference between the two groups (P <0.05). Conclusion Montelukast sodium can effectively reduce mucosal secretion, reduce airway edema, reduce bronchospasm and relieve asthma in children with asthmatic bronchitis. Ambroxol can relieve cough easily because of cough, relieve bronchus Spasm, combined with the effective improvement of children’s lung function, is worthy of clinical promotion and application.